Insights

We offer personalized insights and strategy, and spotlight data in a compelling way to shape policy, communicate value, secure reimbursement, and drive patient access.

Reports

  • MMA IRA Payer Insights Survey

    Magnolia Market Access has just released its fourth IRA Payer Insights Survey. This chartbook provides an overview of findings from the 34 payers and actuaries surveyed and interviewed regarding the future Medicare Drug Price Netoriation Program, Part D Redesign, and the Medicare Prescription Payment Program.

    Read More
  • Gauging how healthcare payers and pharmaceutical manufacturers are reacting to the Inflation Reduction Act of 2022

    Magnolia engaged pharmacy directors, medical directors, and actuaries at health plans and PBMs to understand how payers are designing their plan offerings and adjusting their formularies in the coming years.

    Read More
  • Gathering early perceptions of payer response to the Inflation Reduction Act of 2022

    Magnolia Market Access surveyed medical and pharmacy directors at health plans and pharmacy benefit managers to understand how the IRA will affect the future of the pharmaceutical industry and access to care.

    Read More
  • Gathering early perceptions of payer response to the Inflation Reduction Act of 2022: Medicare Part D Redesign

    Magnolia Market Access surveyed medical and pharmacy directors at health plans and pharmacy benefit managers to understand how the IRA will affect the future of the pharmaceutical industry and access to care.

    Read More
  • screenshot of Enhancing Oncology Model (EOM) Fact Sheet pdf

    Enhancing Oncology Model (EOM) Fact Sheet

    Download to see features of the new healthcare delivery model and value-based care payment system for oncology practices, administered by the Centers for Medicare and Medicaid Services (CMS).

    Read More
  • screenshot of Enhancing Oncology Model (EOM) White Paper: Perspectives from Oncology Practices and the Path Forward in Value-Based Care pdf

    Enhancing Oncology Model (EOM) White Paper: Perspectives from Oncology Practices and the Path Forward in Value-Based Care

    To gather early perceptions of the EOM and understand how oncology practices evaluated participation decisions in the new model, Magnolia facilitated an advisory panel discussion with key opinion leaders.

    Read More

Case Studies

  • Building a Comprehensive Go-To-Market Strategy Through Stakeholder Ecosystem Mapping

    A mid-size client was preparing for a product launch and needed assistance facilitating a successful go-to-market strategy. The company sought to identify and understand the entire stakeholder landscape and create short- and long-term stakeholder engagement strategies to meet the needs of their entire organization.

    Read More
  • Case Study Market Access Segmentation & Identification

    Market Access Segmentation & Identification

    A biopharma company engaged Magnolia Market Access and sister company, 81qd, to collect data and segment provider and payer entities to identify key decision makers for a novel cardiology treatment.

    Read More
  • Using EMR Data to Support Budget Impact Modeling

    Using EMR Data to Support Budget Impact Modeling

    A large pharmaceutical company needed to demonstrate the potential cost savings of placing a new drug on payer formularies.

    Read More
  • Calculating Adherence in the Presence of Variable Follow-up

    Calculating Adherence in the Presence of Variable Follow-Up

    A small-size pharmaceutical company was interested in using real-world evidence to compare adherence between two formulations of an oral oncology treatment for Multiple Myeloma (MM).

    Read More
  • Using Real-world Data to Support a Product Label Change

    Using Real-world Data to Support Product Label Change

    A mid-size pharmaceutical company was interested in obtaining real-world evidence demonstrating the safety and effectiveness of higher dosage chemotherapy for a labeled oncology indication.

    Read More
  • Identifying the Market, Business and Reimbursement Potential for Cell Therapies

    Magnolia was asked to assess which type of cell therapies and disease states offered the greatest potential for development, and also wanted to further understand the benefits of creating an autologous or allogeneic product.

    Read More
  • Optimal Pricing Model Identification

    A new, oral formulation of an existing infused product offered better adherence and less waste, but it was uncertain if these benefits would change payer, provider, and patient pain points or critical success factors for the product’s pricing strategy.

    Read More
  • Understand Perceptions of Your Hub Program

    A company wanted to understand if user perceptions of the hub had improved after implementing changes. Patients and providers previously expressed dissatisfaction with services offered by company’s hub (confusing process, eligibility criteria, who to communicate with), and they recently relaunched the program with enhanced services, a customer portal, and redefined roles for client facing teams.

    Read More
  • Developing a Comprehensive Launch Plan

    Magnolia was engaged as a payer agency of record for a mental health digital therapeutic. Although the company had experience launching drugs in the U.S. market, the novelty of the digital therapeutic space was challenging, and the company did not have experience in mental health, nor a comprehensive launch plan in place across channels.

    Read More
  • Magnolia’s Compendia Submission Helped Client Obtain Payer Coverage

    Magnolia to evaluated the likelihood that a drug compendia would support an off-label dose for a drug with an FDA-approved maximum dose, and helped the client obtain stronger payer coverage with a compendia submission.

    Read More
  • Patient Risk Assessments × Deep 6 AI

    A client needed to develop an algorithm to identify patients at risk for chronic obstructive pulmonary disease (COPD) exacerbations via structured and unstructured EHR data to help clinicians optimize treatments. Magnolia was able to identify patients more precisely through Deep6 AI data than existing algorithms that use claims data alone.

    Read More
  • Assessing the Implications of Financial Requirements on Commercial Copay Assistance Program

    A medium pharmaceutical company was launching a new oral drug in the diabetes space and wanted to understand how having specific income criteria for their commercial copay program would affect patient enrollment and the costs of program operation.

    Read More
  • Telling a Value Story

    A biopharma company engaged Magnolia to develop a value story for an orphan-designated treatment for an auto-immune disorder that was in Phase III development. The company’s product had a novel mechanism of action in comparison to the existing agents in development and would be the first new agent for the disease in years.

    Read More
  • Payer Intelligence to Gather Feedback and Understand Potential Coverage and Reimbursement of an AI CVD Technology

    A small technology company developed an AI-assisted platform that is used to improve accuracy of a CV diagnostic tool. The company asked Magnolia to gather payer feedback on clinical evidence for the platforms and provide insights on future coverage and reimbursement.

    Read More
  • screenshot of Launch planning in an ever-evolving policy and regulatory landscape pdf

    Launch planning in an ever-evolving policy and regulatory landscape

    A development-stage biopharma company engaged Magnolia to help understand the impact that the IRA would have on their product development strategies.

    Read More
  • screenshot of Developing the appropriate regulatory strategy for a patient-centric, therapy-agnostic app pdf

    Developing the appropriate regulatory strategy for a patient-centric, therapy-agnostic app

    A biopharma company engaged Magnolia to assess both the regulatory process as well as the likelihood of uptake of a therapy-agnostic phone app to support the patient journey for a rare pulmonary disease.

    Read More
  • screenshot of Using payer and age mix as the basis for developing a go-to-market strategy for a prelaunch drug pdf

    Using payer and age mix as the basis for developing a go-to-market strategy for a prelaunch drug

    A biopharma company prepping to launch a biosimilar needed to know payer segments and patient age demographics.

    Read More
  • screenshot of Providing program management support in the lead-up to NDA submission and launch pdf

    Providing program management support in the lead-up to NDA submission and launch

    A development-stage biopharma company engaged Magnolia to help put in place an overarching launch road map for a drug that had just received positive phase 3 data.

    Read More
  • screenshot of Designing a coding gameplan for a soon-to-launch infused biologic pdf

    Designing a coding gameplan for a soon-to-launch infused biologic

    A biopharma company needed an inpatient coding analysis for their new medication.

    Read More
  • screenshot of Realigning the Hub pdf

    Realigning the Hub

    A pharmaceutical company offering a hub designed to address patient medication access challenges received customer feedback expressing dissatisfaction from both patients and providers.

    Read More

Posters/Publications

  • Linking EMR With SDOH Data: Insights Across Disease Cohorts

    AMCP Spring 2024 Platinum Poster.

    Read More
  • Social Determinants of Health in a Real-World Adult HIV Population: ICD-10-CM and Consumer Linked Data Identification

    AMCP Spring 2024.

    Read More
  • Payer Insights Survey: Gathering Early Perceptions of Health Plan Response to the Inflation Reduction Act of 2022

    AMCP Spring 2024 Silver Poster.

    Read More
  • Learnings from Linking Closed Claims Patient Cohorts with Consumer SDOH Data

    ISPOR Spring 2024.

    Read More

Presentations

  • Objection Handling: How Should Manufacturers Evolve to Meet the Clinical and Contracting Demands of Payers?

    Navigating Market Access with Magnolia Summer 2024 Presentation.

    Read More
  • Linking EMR With SDOH Data: Insights Across Disease Cohorts Presentation

    AMCP Spring 2024 Platinum Poster and Presentation.

    Read More